Cord Blood Stem Cells
Cord Blood Stem Cells - Related Videos
05:23
Isolating Cord Blood Hematopoietic Stem Cells to Generate Human Immune System Mice
0 Views •
2025
This video demonstrates a technique for generating human immune system (HIS) mice. CD34+ hematopoietic stem cells (HSCs) are isolated from human cord blood buffy coat cells using antibody-coated magnetic beads. The CD34+ HSCs are expanded in a growth medium enriched with cytokines and cryopreserved. Finally, the thawed HSCs are injected into an immunodeficient mouse pup to establish the HIS mouse model.
12:10
Chondrogenic Pellet Formation from Cord Blood-derived Induced Pluripotent Stem Cells
0 Views •
Cited by 19 •
2017
Here, we propose a protocol for chondrogenic differentiation from cord blood mononuclear cell-derived human induced pluripotent stem cells.
14:06
Isolation of Precursor B-cell Subsets from Umbilical Cord Blood
0 Views •
Cited by 2 •
2013
Here we describe a protocol for isolating subsets of precursor B-cells from umbilical cord blood. A sufficient quantity and quality of nucleic acids may be extracted from the cells and used in subsequent assays utilizing DNA or RNA.
07:26
Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood
0 Views •
Cited by 16 •
2017
The goal of this protocol is to isolate endothelial progenitor cells from umbilical cord blood. Some of the applications include using these cells as a biomarker for identifying patients with cardiovascular risk, treating ischemic diseases, and creating tissue-engineered vascular and heart valve constructs.
08:33
Surgical Transplantation of Mouse Neural Stem Cells into the Spinal Cords of Mice Infected with Neurotropic Mouse Hepatitis Virus
0 Views •
Cited by 14 •
2011
The transplantation of mouse neural stem cells (NSCs) into the spinal cords of mice with established demyelination is detailed. The preparation of NSCs, the laminectomy of thoracic vertebra 9 (T9), and transplantation of NSCs is outlined along with the pre- and post-operative care of the mice.
FAQs
Cell dose affects how many hematopoietic stem and progenitor cells are available to establish blood-forming tissue in the recipient. Since cord blood transplantation depends partly on dose, clinicians consider this measure together with tissue compatibility and storage quality when selecting a unit, because each factor can influence the likelihood and course of engraftment.
Tissue compatibility helps determine whether a cord blood unit is suitable for a particular recipient. The cells must be infused into a compatible recipient, so compatibility is assessed alongside cell dose and storage quality rather than treated as an isolated criterion. This selection process supports the goal of achieving engraftment after transplantation.
Self-renewal and differentiation support different stages of blood-system recovery. Self-renewal maintains the stem-cell pool, while differentiation produces progeny that become red blood cells, white blood cells, and platelets. Together, these properties allow infused cells to rebuild blood-forming tissue through continuing production of multiple blood-cell types.
Cord blood transplantation becomes especially relevant when a fully matched adult donor cannot be found. In that setting, clinicians can consider a cord blood unit if its tissue compatibility, cell dose, and storage quality are acceptable. This option expands the potential donor sources available for selected patients requiring replacement of blood-forming tissue.
Collection occurs from blood remaining in the umbilical cord and placenta after birth, making the timing of collection part of the procedure. After collection, storage quality becomes clinically important because the unit may later be evaluated for transplantation. The collected material is considered with compatibility and cell dose before infusion into a recipient.
Before infusion, clinicians assess the candidate cord blood unit using the factors identified as important for clinical use: cell dose, tissue compatibility, and storage quality. The selected cells are then infused into the compatible recipient, after which engraftment is monitored as the cells migrate to bone marrow and begin rebuilding blood-forming tissue.
Medically, cord blood transplantation is used in selected cases of leukemia, lymphoma, inherited blood disorders, and immune deficiencies. It is particularly relevant when rebuilding blood-forming tissue could address the patient’s disease and a fully matched adult donor is unavailable. These applications place the technique within treatment strategies for malignant and inherited conditions.